Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | PYGB | P11216 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14191378 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL14191382 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL14025371 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL14278435 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL10176794 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL12221718 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL23640046 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL9914077 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL21339944 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB | |
| SCHEMBL12242433 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409650-A1 | COMPOSITIONS AND METHODS FOR ASCAROSIDE MODIFICATION OF MAMMALIAN MICROBIOTA | HOLOCLARA INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-10010535-B2 | Desferrithiocin analogs and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409650-A1 | COMPOSITIONS AND METHODS FOR ASCAROSIDE MODIFICATION OF MAMMALIAN MICROBIOTA | SI, FABP2, ALPI | LGALS1 195/4885LGALS3 164/4885LGALS9 601/4885 |
| US-10010535-B2 | Desferrithiocin analogs and uses thereof | FECH, TFRC, FTH1 | LGALS1 2325/4885LGALS3 2758/4885LGALS9 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.